Use of telemedicine and helicopter transport to improve stroke care in remote locations

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Opinion statement: Intravenous recombinant tissue plasminogen activator is the only medication approved by the US Food and Drug Administration for treatment of acute stoke. Despite established efficacy, less than 3% of stroke patients receive treatment, and that number is even smaller for patients living in remote locations. This is in part due to a lack of neurologists and stroke specialists in these rural communities. The traditional model of "ship and drip" wastes crucial time, resulting in delays or loss of treatment. In this review, we discuss strategies to overcome geographic disparities in stroke care and improve acute treatment in remote locations. Helicopter transport from field to stroke center is one option to rapidly deliver patients to stroke centers. However, geography, weather, and unnecessary transport are potential drawbacks. Alternatively, "telestroke" facilitates remote evaluation of acute stroke patients via an audiovisual link and transmission of computerized tomography images. Despite the physical separation, stroke specialists are able to examine patients, review brain imaging and make correct treatment decisions; transfer to a stroke center can then be performed as appropriate. A cost-benefit analysis of telestroke is needed, although the recent proliferation of telestroke networks suggests an economic asset to some hospital systems.

Original languageEnglish (US)
Pages (from-to)215-224
Number of pages10
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Aircraft
Telemedicine
Stroke
X Ray Tomography
Therapeutics
Geography
Ships
Weather
Tissue Plasminogen Activator
Rural Population
United States Food and Drug Administration
Neuroimaging
Cost-Benefit Analysis
Economics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{7add3b6414e94d428d98fcfed8064ebd,
title = "Use of telemedicine and helicopter transport to improve stroke care in remote locations",
abstract = "Opinion statement: Intravenous recombinant tissue plasminogen activator is the only medication approved by the US Food and Drug Administration for treatment of acute stoke. Despite established efficacy, less than 3{\%} of stroke patients receive treatment, and that number is even smaller for patients living in remote locations. This is in part due to a lack of neurologists and stroke specialists in these rural communities. The traditional model of {"}ship and drip{"} wastes crucial time, resulting in delays or loss of treatment. In this review, we discuss strategies to overcome geographic disparities in stroke care and improve acute treatment in remote locations. Helicopter transport from field to stroke center is one option to rapidly deliver patients to stroke centers. However, geography, weather, and unnecessary transport are potential drawbacks. Alternatively, {"}telestroke{"} facilitates remote evaluation of acute stroke patients via an audiovisual link and transmission of computerized tomography images. Despite the physical separation, stroke specialists are able to examine patients, review brain imaging and make correct treatment decisions; transfer to a stroke center can then be performed as appropriate. A cost-benefit analysis of telestroke is needed, although the recent proliferation of telestroke networks suggests an economic asset to some hospital systems.",
author = "Mihaela Saler and Switzer, {Jeffrey A} and Hess, {David C}",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s11936-011-0124-y",
language = "English (US)",
volume = "13",
pages = "215--224",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Use of telemedicine and helicopter transport to improve stroke care in remote locations

AU - Saler, Mihaela

AU - Switzer, Jeffrey A

AU - Hess, David C

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Opinion statement: Intravenous recombinant tissue plasminogen activator is the only medication approved by the US Food and Drug Administration for treatment of acute stoke. Despite established efficacy, less than 3% of stroke patients receive treatment, and that number is even smaller for patients living in remote locations. This is in part due to a lack of neurologists and stroke specialists in these rural communities. The traditional model of "ship and drip" wastes crucial time, resulting in delays or loss of treatment. In this review, we discuss strategies to overcome geographic disparities in stroke care and improve acute treatment in remote locations. Helicopter transport from field to stroke center is one option to rapidly deliver patients to stroke centers. However, geography, weather, and unnecessary transport are potential drawbacks. Alternatively, "telestroke" facilitates remote evaluation of acute stroke patients via an audiovisual link and transmission of computerized tomography images. Despite the physical separation, stroke specialists are able to examine patients, review brain imaging and make correct treatment decisions; transfer to a stroke center can then be performed as appropriate. A cost-benefit analysis of telestroke is needed, although the recent proliferation of telestroke networks suggests an economic asset to some hospital systems.

AB - Opinion statement: Intravenous recombinant tissue plasminogen activator is the only medication approved by the US Food and Drug Administration for treatment of acute stoke. Despite established efficacy, less than 3% of stroke patients receive treatment, and that number is even smaller for patients living in remote locations. This is in part due to a lack of neurologists and stroke specialists in these rural communities. The traditional model of "ship and drip" wastes crucial time, resulting in delays or loss of treatment. In this review, we discuss strategies to overcome geographic disparities in stroke care and improve acute treatment in remote locations. Helicopter transport from field to stroke center is one option to rapidly deliver patients to stroke centers. However, geography, weather, and unnecessary transport are potential drawbacks. Alternatively, "telestroke" facilitates remote evaluation of acute stroke patients via an audiovisual link and transmission of computerized tomography images. Despite the physical separation, stroke specialists are able to examine patients, review brain imaging and make correct treatment decisions; transfer to a stroke center can then be performed as appropriate. A cost-benefit analysis of telestroke is needed, although the recent proliferation of telestroke networks suggests an economic asset to some hospital systems.

UR - http://www.scopus.com/inward/record.url?scp=79955846683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955846683&partnerID=8YFLogxK

U2 - 10.1007/s11936-011-0124-y

DO - 10.1007/s11936-011-0124-y

M3 - Article

VL - 13

SP - 215

EP - 224

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 3

ER -